Interleukin licenses DNA-based weight management technology from GeneOb

By Lisa Kerner

Charlotte, N.C., June 21 - Interleukin Genetics said it has exclusively licensed technology from GeneOb, Inc. that uses genetic markers to determine the risk of weight gain and response to weight-loss programs.

The company plans to use the GeneOb algorithm in the development of a genetic weight management test with its commercialization partner, Alticor.

Interleukin said the GeneOb genetic test panel and algorithm will help identify the specific biological mechanisms that contribute to weight gain and response to diet and exercise for a more targeted, personalized weight management program.

Under the agreement, Interleukin can market a weight management genetic test based on GeneOb technology in North America through the multi-level marketing channel.

GeneOb and Interleukin will negotiate for a predetermined period licenses for additional undisclosed products.

Financial terms of the agreement were not disclosed.

"Our license to this technology provides a strong scientific platform from which we can apply our product development expertise to develop a DNA-based tool for weight management," president and chief executive officer Kenneth Kornman said in a company news release.

"We believe that this product may provide substantial aid to many individuals who need to address and manage weight problems."

About 66% of U.S. adults and 17% of adolescents are overweight, according to the National Center for Health Statistics.

Based in Amherst, N.Y., GeneOb develops new assessment methods and tools for the treatment and prevention of obesity, diabetes mellitus and heart disease.

Interleukin, located in Waltham, Mass., is a biotechnology company focused on developing and commercializing personalized health products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.